CSL BEHRING LLC

ACTIVE

900 Broken Sound Pkwy NW Ste 4000, Boca Raton, Florida, United Stateswww.cslbehring.comSubsidiary5,001–10,000 employeesEstablished: 1904-01-01

Clinical Trials

103

79 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1904

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

77.7%

Phase 3

9.7%

Phase 2

3.9%

Phase 4

1.9%

Not Applicable

1.0%

Phase 2/3

1.0%

Trial Status Distribution

Active, not recruiting

76.7%

Completed

7.8%

Recruiting

15.5%

Clinical Trials

Trials sponsored by this organization (103)

Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease

Phase 2

Recruiting

May 202612 participants

Phase 4, double-blind study evaluating the response on computed tomography (CT) lung density decline rates of Respreeza / Zemaira weekly for 3 years in adults with alpha1 antitrypsin deficiency (AATD)

Phase 4

Recruiting

Mar 202633 participants

Efficacy and safety of vamifeport in adult subjects with HFE-related hereditary hemochromatosis

Phase 2

Recruiting

Feb 202650 participants

A phase III trial investigating a gene therapy (AAV-hFIXco-Padua, AMT061), in adult patients with severe or moderately severe haemophilia B, to firstly evaluate if it's effective, and secondly further describe it's safety profile.

Phase 1

Recruiting

interventional

Jul 202471 participants

A Phase I/IIb extension study assessing the long-term safety and efficacy of a gene therapy (AAV5-hFIX) previously administered to adult patients with severe or moderately severe haemophilia B during the CT-AMT-060-01 Phase I/II study.

Phase 1

Recruiting

interventional

May 20249 participants

The safety and efficacy of Alpha-1 Antitrypsin (AAT) for the prevention of graft-versus-host disease (GVHD) in patients receiving hematopoietic cell transplant.

Phase 1

Recruiting

interventional

Apr 2024310 participants

A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with dermatomyositis (DM)

Phase 1

Active, not recruiting

interventional

Mar 2024126 participants

ong-term safety and efficacy of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema attacks

Phase 1

Active, not recruiting

interventional

Mar 2024161 participants

Page 1 of 13

Approvals

Approvals by Agency

PHILIPPINES

Philippines FDA

Approvals

Recent Approvals

Alburx

PHILIPPINES

03 January 2023

News

No news articles found

Back to Organizations